In both murine carcinoma models, N-IL15/PDL1 was well-tolerated and displayed comparable or improved anti-tumor efficacy versus previous studies with N-IL15 or PD-L1 monotherapy or N-IL15 plus PD-L1 combination therapy. This evidence concerns the gene IL15 and carcinoma.